Friday, July 10, 2026

Drug profile · INN

navepegritide

navepegritide (YUVIWEL) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — navepegritide
US status
approved
Class
Route
SUBCUTANEOUS
Patents
0
Programs
1
Data quality
0.84

Quick answer

navepegritide (YUVIWEL) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.

Key facts

INN navepegritide
Brand YUVIWEL
Route SUBCUTANEOUS
Formulation POWDER

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. ASND0030 Phase 2 · Anaxis Pharma · Achondroplasia in Children and Adolescents

Frequently asked questions

What is navepegritide?

navepegritide (YUVIWEL) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.

What is the brand name for navepegritide?

YUVIWEL is a marketed brand name for navepegritide. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of navepegritide?

navepegritide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.